Application of vitamin D analogue in treatment of severe fever with thrombocytopenia syndrome virus infection
By using vitamin D analogs such as ducalciferol, alphacalciferol, and alpha-hydroxyvitamin D4, the problem of the lack of effective anti-SFTSV drugs has been solved, achieving effective inhibition and treatment of SFTSV.
Patent Information
- Application Number
- CN202411260099.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Currently, there is a lack of safe and effective specific antiviral drugs for fever with thrombocytopenia syndrome virus (SFTSV) infection in clinical practice, and there is an urgent need to develop new compounds to treat the disease caused by this virus.
Vitamin D analogues, such as doxorubicin, alphacalciferol, and alpha-hydroxyvitamin D4, are used to treat SFTSV infection or diseases caused by it by inhibiting SFTSV replication and reducing viral particle release.
These vitamin D analogs significantly inhibited SFTSV viral replication in vitro and in vivo, reduced viral load, prolonged survival time, improved survival rate, and reduced cytopathic effects.
Smart Images

Figure CN118903159A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the use of vitamin D analogs in preparing a medicament for treating HFTS virus infection or a disease caused by HFTS virus infection in a subject. Background Art
[0002] Severe fever with thrombocytopenia syndrome virus (SFTSV), also known as Dabie bandavirus. SFTSV is a tick-borne virus of the Bunyavirales order, Phenuiviridae family, Bandavirus genus, which can cause severe fever with thrombocytopenia syndrome (SFTS). In 2018, the World Health Organization (WHO) listed SFTSV as one of the emerging infectious diseases that need to be paid special attention to during the annual research and development blueprint for key diseases.
[0003] The clinical manifestations of SFTSV are mainly characterized by fever, thrombocytopenia and leukopenia, often accompanied by symptoms such as fatigue, loss of appetite, nausea, vomiting, etc. Some patients are accompanied by headaches, muscle aches, diarrhea, etc., and often have swollen lymph nodes in the neck and groin. Most young patients have a good prognosis, while patients with advanced age, low immunity, and serious underlying diseases are prone to severe illness. Severe patients experience extreme fatigue, loss of appetite, mental depression, skin ecchymosis, increased muscle tension, drowsiness, trance or lethargy and other neurological symptoms, and severe patients even die. According to the "Diagnosis and Treatment Program for Fever with Thrombocytopenia Syndrome" (2023 edition) issued by the National Health Commission of China, clinical treatment mainly adopts symptomatic supportive treatment and treatment for complications. So far, there is no approved SFTSV vaccine or specific antiviral drug available clinically. Therefore, it is urgent to develop new safe, effective and specific anti-SFTSV candidate compound varieties. Summary of the invention
[0004] The present invention aims to find compounds with antiviral activity against SFTSV. The present inventors have found through creative research that the vitamin D analogues shown in formula I have the function of inhibiting the replication of SFTSV and can be used to treat SFTSV infection or diseases caused by SFTSV infection.
[0005] The present invention provides the use of a compound represented by formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof in the preparation of a medicament, wherein the medicament is used to treat a fever with thrombocytopenia syndrome virus infection or a disease caused by the fever with thrombocytopenia syndrome virus infection in a subject.
[0006]
[0007] in: represents a single bond or a double bond,
[0008] R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-6 Alkyl or C 1-6 Alkyl-C(O)-O-.
[0009] The present invention also provides the use of a pharmaceutical composition in the preparation of a drug, wherein the pharmaceutical composition contains the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or hydrates, and a pharmaceutically acceptable carrier, and the drug is used to treat FET virus infection or a disease caused by FET virus infection in a subject.
[0010] The present invention also provides the use of the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates in the preparation of a drug for inhibiting the replication or reproduction of fever with thrombocytopenia syndrome virus in a subject.
[0011] The present invention also provides the use of a pharmaceutical composition in the preparation of a drug for inhibiting the replication or reproduction of fever with thrombocytopenia syndrome virus in a subject, wherein the pharmaceutical composition contains the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or hydrates, and a pharmaceutically acceptable carrier.
[0012] The present invention also provides the use of the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates in the preparation of drugs as inhibitors of fever with thrombocytopenia syndrome viruses.
[0013] The present invention also provides the use of a pharmaceutical composition in the preparation of a drug used as a viral inhibitor for fever with thrombocytopenia syndrome, wherein the pharmaceutical composition contains the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or hydrates, and a pharmaceutically acceptable carrier.
[0014] The present invention also provides a pharmaceutical composition for treating FETV infection or a disease caused by FETV infection in a subject, wherein the pharmaceutical composition contains the compound represented by Formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates.
[0015] The present invention also provides a pharmaceutical composition for inhibiting the replication or reproduction of fever with thrombocytopenia syndrome virus in a subject, wherein the pharmaceutical composition contains the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates.
[0016] The present invention also provides a pharmaceutical composition as a viral inhibitor of fever with thrombocytopenia syndrome, wherein the pharmaceutical composition contains the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates.
[0017] The present invention also provides a method for treating FETV infection or a disease caused by FETV infection in a subject, comprising administering to a subject in need thereof an effective amount of the compound represented by Formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates.
[0018] The present invention also provides a method for inhibiting the activity of fever with thrombocytopenia syndrome virus in a subject, comprising: contacting the subject with the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates, or delivering it to the subject.
[0019] The present invention also provides a method for inhibiting the activity of fever with thrombocytopenia syndrome virus in vivo or in vitro, which comprises: contacting the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates with the cells.
[0020] The present invention also provides the compound represented by Formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates, which are used to treat FET virus infection or diseases caused by FET virus infection in subjects.
[0021] The present invention also provides the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates, which are used to inhibit the replication or reproduction of fever with thrombocytopenia syndrome virus in a subject.
[0022] The present invention also provides the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates, which are used as inhibitors of fever with thrombocytopenia syndrome virus.
[0023] In some embodiments, the compound represented by Formula I, its geometric isomer, its pharmaceutically acceptable salt, its solvate or its hydrate is used in a subject:
[0024] (1) Reduce viremia in the body,
[0025] (2) Reduce the viral nucleic acid load level of SFTSV-infected cells,
[0026] (3) reduce the production of progeny infectious virus particles, and / or
[0027] (4) Prolong survival time.
[0028] In some embodiments, in the pharmaceutical composition, the compound represented by Formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates are present in an effective amount.
[0029] In some embodiments, the disease caused by FET virus infection is FET.
[0030] In some embodiments, the disease caused by FET virus infection is selected from acute fever, cough, fatigue, gastrointestinal symptoms, leukopenia and / or thrombocytopenia, multi-organ hemorrhage, disseminated intravascular coagulation (DIC), and viral encephalitis.
[0031] In some embodiments, R1, R2 and R3 in Formula I are each independently hydrogen, hydroxyl, C 1-4 Alkyl or C 1-4 Alkyl-C(O)-O-.
[0032] In some embodiments, R1, R2 and R3 in Formula I are each independently hydrogen, hydroxyl, C 1-3 Alkyl or C 1-3 Alkyl-C(O)-O-.
[0033] In some embodiments, R1, R2 and R3 in Formula I are each independently hydrogen, hydroxyl, methyl, ethyl, CH3-C(O)-O- or CH3-CH2-C(O)-O-.
[0034] In some embodiments, in Formula I, R1 is hydroxy, R2 is hydrogen, hydroxy or methyl, and R3 is hydrogen, hydroxy or methyl.
[0035] In some embodiments, in Formula I, R1 is hydroxy, R2 is hydrogen, hydroxy or methyl, and R3 is hydrogen or hydroxy.
[0036] In some embodiments, in Formula I, R1 is hydroxy, R2 is hydrogen or methyl, and R3 is hydrogen.
[0037] In some embodiments, the compound of Formula I is doxorcalciferol, alphacalciferol or alpha hydroxyvitamin.
[0038] In some embodiments, the subject is a mammal, such as bovine, equine, ovine, porcine, canine, feline, rodent, primate, preferably human, cat, dog or pig. In some embodiments, the subject suffers from FTTS virus infection.
[0039] The pharmaceutical composition of the present invention can be formulated into any dosage form known in the medical field, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injection and concentrated solutions for injection), inhalants, sprays, etc. The preferred dosage form depends on the intended mode of administration and therapeutic use. The pharmaceutical composition of the present invention should be sterile and stable under production and storage conditions. A preferred dosage form is an injection. Such injections can be sterile injection solutions. For example, sterile injection solutions can be prepared by the following method: the pharmaceutical composition of the present invention is mixed with a necessary dose in an appropriate solvent, and optionally, other desired ingredients (including but not limited to, pH regulators, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof) are mixed at the same time, followed by filtration and sterilization. In addition, sterile injection solutions can be prepared as sterile lyophilized powders (for example, by vacuum drying or freeze drying) for easy storage and use. Such sterile lyophilized powders can be dispersed in a suitable vehicle, such as sterile pyrogen-free water, before use.
[0040] In addition, the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or hydrates thereof, of the present invention may be present in a pharmaceutical composition in the form of a unit dosage for easy administration.
[0041] Pharmaceutical composition of the present invention can be used by any suitable method known in the art, including but not limited to, oral, oral, sublingual, eyeball, local, parenteral, rectal, leaf sheath, endocytoplasmic reticulum groove, groin, bladder, local (such as, powder, ointment or drops), or nasal route. But, for many therapeutic uses, preferred route of administration / mode is parenteral administration (such as intravenous injection, subcutaneous injection, intraperitoneal injection, intramuscular injection, intratumor injection). Technicians should understand that route of administration and / or mode will change according to the intended purpose. In part preferred embodiments, pharmaceutical composition of the present invention is given by intravenous infusion or injection.
[0042] The pharmaceutical composition of the present invention may include a "therapeutically effective amount" of the compound of formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates. "Therapeutically effective amount" refers to an amount sufficient to cure or at least partially prevent the disease and its complications in patients who have already suffered from the disease. The therapeutically effective amount of the compound of formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates of the present invention may vary according to the following factors: the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight and sex, the mode of administration of the drug, and other treatments administered simultaneously, etc. The preferred dosage here is between 0.001-1000 mg / kg body weight / day.
[0043] In the present application, the dosage regimen can be adjusted to obtain the best intended response (e.g., treatment or prevention response). For example, a single dose can be administered, multiple doses can be administered over a period of time, or the dosage can be proportionally reduced or increased according to the urgency of the treatment situation.
[0044] Definition of terms
[0045] In this application, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the virology, biochemistry, and immunology laboratory operation procedures used herein are conventional procedures widely used in the corresponding fields. At the same time, in order to better understand this application, the definitions and explanations of relevant terms are provided below.
[0046] When the terms "for example," "such as," "including," "comprising," or variations thereof are used herein, these terms will not be considered as limiting terms, but will be interpreted to mean "but not limited to" or "not limited to."
[0047] The terms "a" and "an" and "the" and similar referents in the context of describing the application (especially in the context of the following claims) should be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
[0048] As used herein, the term "and / or" should be considered as a specific disclosure of each of two or more specified features or elements, as well as any combination of two or more features or elements. Thus, the term "and / or" used in phrases such as "A and / or B" is intended to include "A and B", "A or B", "A" (alone), and "B" (alone).
[0049] As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH regulators, surfactants, adjuvants, ionic strength enhancers, diluents, agents that maintain osmotic pressure, agents that delay absorption, and preservatives. For example, pH regulators include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Agents that maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like. Agents that delay absorption include, but are not limited to, monostearate and gelatin. Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols and polyols (such as glycerol), etc. Stabilizers have the meanings generally understood by those skilled in the art, and are capable of stabilizing the desired activity of the active ingredient in the drug, including but not limited to sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin or casein) or their degradation products (such as lactalbumin hydrolysate), etc.
[0050] As used herein, the term "treatment" refers to a method implemented in order to obtain a beneficial or desired clinical outcome. For the purposes of the present application, a beneficial or desired clinical outcome includes, but is not limited to, alleviating symptoms, reducing the scope of the disease, stabilizing (i.e., no longer worsening) the state of the disease, delaying or slowing the development of the disease, improving or alleviating the state of the disease and alleviating symptoms (whether partially or completely), whether detectable or undetectable. In addition, "treatment" may also refer to, compared to the expected survival period (if not treated), extending the survival period.
[0051] As used herein, the term "fever with thrombocytopenia syndrome virus" is also known as Dabie bandavirus, a tick-borne virus of the Bunyavirales order, Phenuiviridae family, genus Bandavirus, which can cause severe fever with thrombocytopenia syndrome (SFTS)
[0052] Beneficial technical effects of the present invention
[0053] The vitamin D analogues shown in formula I provided by the present invention can reduce the cytopathic effect caused by SFTSV infection on cells, inhibit the replication of the SFTSV viral genome, and reduce the release of SFTSV progeny virus particles in cell culture.
[0054] The vitamin D analogues shown in formula I provided by the present invention can reduce viremia in mice, prolong the survival time of ICR suckling mice infected with a lethal dose of SFTSV, and improve their survival rate.
[0055] The intracellular action characteristics of the vitamin D analogues of formula I provided by the present invention include: being able to reduce the viral nucleic acid load level of SFTSV-infected cells and the production of progeny infectious virus particles at micromolar concentrations.
[0056] The vitamin D analogues shown in formula I provided by the present invention can be used to treat SFTSV infection or diseases caused by SFTSV infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] Figure 1 The structural formulas of doxorcalciferol, alphacalciferol and alpha-hydroxyvitamin D4 are shown, wherein A is doxorcalciferol (R1 = hydroxyl, R2 = methyl, R3 = hydrogen); B is alphacalciferol (R1 = hydroxyl, R2 = hydrogen bond, R3 = hydrogen); C is alpha hydroxy vitamin D4 (R1 = hydroxyl, R2 = methyl, R3 = hydrogen).
[0058] Figure 2 The anti-SFTSV activity and cytotoxicity of doxorcalciferol, alphacalciferol and alpha-hydroxyvitamin D4 are shown in Figure 5, where A, B and C are shown in Huh7 cells at 100 TCID 50 Virus infection dose, treated with different doses of vitamin D analogs, three vitamin D analogs inhibited SFTSV infection in a dose-dependent manner in Huh7 cell line and significantly reduced the cytopathic effect (CPE) caused by SFTSV infection. The abscissa represents the concentration of doxorcalciferol, alphacalciferol or alpha-hydroxyvitamin D4, and the left and right Y axes represent the virus inhibition rate and cytotoxicity, respectively.
[0059] Figure 3 The results show that doxorcalciferol, alphacalciferol and alpha-hydroxyvitamin D4 can reduce viral RNA replication and the release of infectious virus particles, where A, B and C respectively show the expression levels of intracellular viral RNA after Huh7 cells were treated with doxorcalciferol, alpha-calciferol and alpha-hydroxyvitamin D4 at specified drug concentrations and infected with MOI = 0.01 and incubated for 48 hours; D, E and F respectively show the inhibitory effect of cells treated with specified drug concentrations of doxorcalciferol, alpha-calciferol and alpha-hydroxyvitamin D4 on the formation of infectious virus particles in the cell supernatant.
[0060] Figure 4 Experimental results showing that doxorcalciferol and alphacalciferol reduce viremia in vivo and protect mice from lethal infection with SFTSV. The results showed that three treatments of vitamin D analogs before, during, and after SFTSV infection in six-week-old BALB / c mice significantly reduced viremia in BALB / c adult mice (A, D); one-day-old ICR suckling mice were infected with SFTSV with an inoculum of 1×10 5 PFU / mouse. Treatment with doxorcalciferol and alphacalciferol, respectively, can effectively improve the protection rate and prolong the survival time of ICR suckling mice (B, C), while having no significant effect on the weight gain of ICR suckling mice (E, F).
[0061] Figure 5 It shows that doxorcalciferol, alphacalciferol and alpha hydroxyvitamin D4 mainly act in the post-entry stage of viral infection, where A shows a schematic diagram of the drug addition timing, the Mock group is the virus control group, the virus-infected cells do not receive drug treatment, stages I to IV represent different stages of the virus life cycle, B, C and D respectively show the inhibitory effects of doxorcalciferol, alphacalciferol and alpha hydroxyvitamin D4 on different stages of the SFTSV virus life cycle, and T-705 (favipiravir) is used as a positive control. DETAILED DESCRIPTION
[0062] The substantive content of the present invention is further described below in conjunction with specific embodiments of the present invention. It should be understood that the following examples are only used to illustrate the present invention, but are not intended to limit the scope of protection of the present invention. In the following examples, if specific conditions are not specified, they are carried out according to conventional conditions or manufacturer recommendations. The raw materials used are not specified by the manufacturer, and are all conventional products that can be obtained commercially.
[0063] Although many materials and operating methods used in the following examples are well known in the art, the present invention is still described in as much detail as possible. It is clear to those skilled in the art that the materials and operating methods used in the following examples are well known in the art unless otherwise specified.
[0064] The experimental materials used in the embodiment of the present invention include: human liver cancer cells (Huh7 cell) purchased from the National Experimental Cell Resource Sharing Platform (item number: SCSP-526), SFTSV strains were isolated and stored from clinical samples by this laboratory according to standard operating procedures (GenBank accession numbers: MZ561690, MZ561691 and MZ561692), FBS (purchased from Gibco, item number 2466381RP), penicillin-streptomycin double antibody (purchased from Gibco, item number: 2321152), DMEM (purchased from Gibco, item number 2892358), PBS (purchased from Gibco, item number 6123093), 0.25% trypsin-EDTA (purchased from Gibco, item number 2660239), Cell-Titer Luminescent Cell Viability Kit (purchased from Promega, Catalog No.: G7572), white bottom transparent 96-well plate (purchased from Corning, Catalog No.: 165306), doxorcalciferol (purchased from MCE, Catalog No.: HY-32348), alphacalciferol (purchased from MCE, Catalog No.: HY-10003), alpha hydroxyvitamin D4 (purchased from MCE, Catalog No.: HY-13249), TRIzol reagent (purchased from Invitrogen, Catalog No.: 15596026), OneStep PrimeScript TMRT-PCR kit (purchased from Takara, catalog number: RR47Q), low melting point agarose (purchased from Promega, catalog number: V2111), 1% ammonium oxalate crystal violet stain (purchased from Meilun Biotechnology, catalog number MA0158), chloroform (purchased from Sinopharm Group, catalog number 20230816), isopropanol (purchased from Sinopharm Group, catalog number 20240123), 75% ethanol (purchased from Sinopharm Group, catalog number 20231118), enzyme-free water (purchased from Beijing Lanjieke Technology Co., Ltd., catalog number 23219717), formaldehyde (purchased from Sinopharm Group, catalog number 20190606), 12-well plate (purchased from Corning, catalog number: 3512), the standard plasmid of SFTSV and qRT-PCR primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0065] The structural formulas of doxorcalciferol, alphacalciferol and alpha-hydroxyvitamin D4 are as follows Figure 1 shown.
[0066] Example 1 Anti-SFTSV Activity and Cytotoxicity Experiment of Vitamin D Analogs
[0067] (1) Experimental plan
[0068] The density of Huh7 cells was about 5 × 10 3 cells / well, 100 μL / well was inoculated into a white bottom transparent 96-well plate and placed in a 37°C, 5% CO2 incubator overnight. Discard the liquid and add 150 μL / well DMEM medium containing 2% fetal bovine serum (FBS). The compound treatment group was added with 50 μL of DMEM medium containing 2% FBS containing the compound to be tested (the final concentrations of doxorubicin and alpha-hydroxyvitamin D4 were 9 μM, 3 μM, 1 μM, 0.33 μM, 0.11 μM, and 0.04 μM, and the final concentrations of alpha-calciferol were 5 μM, 1.67 μM, 0.56 μM, 0.19 μM, and 0.03 μM). The cell control group was supplemented with 50 μL of DMEM medium containing 2% FBS. The above-mentioned white bottom transparent 96-well plate inoculated with cells was transferred to a humidified box and returned to a 37°C, 5% CO2 incubator for continued culture. After 6 days of cell culture, use Luminescent Cell Viability Assay was used to detect cell viability and calculate the half-cytotoxic concentrations (CC 50 ).
[0069] The density of Huh7 cells was about 5 × 10 3100 μL / well of DMEM medium containing 2% FBS was added to each well. 50 μL of 100 TCID / well of compound treatment group was added to each well. 50 SFTSV virus dilution and 50 μL DMEM medium containing the test compound and 2% FBS (the final concentrations of calciferol and alpha-hydroxyvitamin D4 were 9 μM, 3 μM, 1 μM, 0.33 μM, 0.11 μM, and 0.04 μM, and the final concentrations of alpha-calciferol were 5 μM, 1.67 μM, 0.56 μM, 0.19 μM, and 0.03 μM), and the virus control group was added with 50 μL 100 TCID 50 The SFTSV virus dilution was supplemented with 50 μL of DMEM medium containing 2% FBS, and the cell control group was supplemented with 100 μL of DMEM medium containing 2% FBS. The white bottom 96-well plate inoculated with cells was transferred to a wet box and returned to a 37°C, 5% CO2 incubator for continued culture until the virus group cells were completely diseased. Prepare the test solution in advance at a ratio of 7:3 for Luminescent Cell Viability Assay, discard the supernatant, add 100 μL / well of the test solution, transfer to a horizontal shaker and shake gently for 5 minutes, let stand at room temperature for 3 minutes, protect from light during the test, use a multifunctional microplate reader to test the luminescence index by testing cell viability, and calculate the half-maximal effective concentration (EC) of the corresponding compound. 50 ).
[0070] (2) Data Analysis
[0071]
[0072] The experiments were repeated three times independently, and scatter plots were drawn using GraphPad Prism 9. 50 and CC 50 The data were calculated using the parametric nonlinear regression model of Origin9.0 software and presented as “mean ± standard deviation”.
[0073] (3) Experimental results
[0074] The experimental results are shown in Tables 1 to 3 and Figure 2 As shown: Doxorcalciferol, alphacalciferol and alpha-hydroxyvitamin D4 can inhibit the cytopathic effect of virus-induced Huh7 cells in a dose-dependent manner.50 Value and CC 50 The values were 1.98±1.30μM and 11.11±0.11μM, respectively. The EC values of alphacalcidol on Huh7 cells 50 Value and CC 50 The values were 1.59 ± 0.35 μM and 6.79 ± 0.99 μM, respectively. The EC of alpha-hydroxyvitamin D4 on Huh7 cells 50 Value and CC 50 The values were 2.72 ± 0.40 μM and 11.59 ± 0.24 μM, respectively.
[0075] Table 1. Cytopathic protection and cytotoxicity experiments of doxorubicin
[0076] Concentration (μM) 9 3 1 0.33 0.11 0.04 Inhibition rate (%) 76.19±5.76 52.71±7.54 36.78±10.49 -4.27±7.82 11.66±3.63 8.78±12.42 Cytotoxicity (%) -10.33±1.0 -6.06±0.46 -1.23±1.50 0.00±2.52 -1.15±2.01 0.99±1.73
[0077] Table 2. Cytopathic protection and cytotoxicity experiments of Alphacalcidol
[0078] Concentration (μM) 5 1.67 0.56 0.19 0.06 Inhibition rate (%) 92.97±3.92 61.65±16.65 11.55±14.94 -3.00±8.57 3.10±7.70 Cytotoxicity (%) -0.16±1.68 -5.46±1.70 -4.11±1.67 3.48±1.68 -4.86±0.88
[0079] Table 3. Cytopathic protection and cytotoxicity experiments of alpha-hydroxyvitamin D4
[0080] Concentration (μM) 9 3 1 0.33 0.11 0.04 Inhibition rate (%) 81.68±9.73 46.64±13.24 31.66±13.29 21.01±10.98 12.49±9.74 -8.44±5.62 Cytotoxicity (%) -13.41±2.06 -9.74±0.16 -5.64±1.13 3.87±0.49 -4.36±1.00 -4.24±0.58
[0081] Example 2 Experimental study on the inhibitory effect of vitamin D analogs on viral RNA replication and release of infectious viral particles
[0082] (1) Experimental plan
[0083] The density of Huh7 cells was about 2 × 10 5Cells / well, 1mL / well inoculated in a 12-well plate, placed in an incubator overnight. Set up a virus control group and a compound treatment group separately. Discard the supernatant, add 500μL / well DMEM medium containing 2% FBS and 500μL virus dilution (infection dose MOI = 0.01) to the virus control group, and add 500μL virus dilution (infection dose MOI = 0.01) and 500μL test compound dilution (3-fold concentration gradient dilution with DMEM medium containing 2% FBS, a total of 5 compound concentrations) to the compound treatment group. Transfer the cell culture plate to an incubator and incubate for 48h, collect the supernatant, store at -80℃ for use, wash the lower layer of cells with PBS, add 1mL / well TRIzol lysis solution, let stand at room temperature for 1min, and transfer the sample to a 1.5mL EP tube. Add 200μL / tube of chloroform to each sample, mix well, and let stand at room temperature for 3min. Centrifuge at 12000rpm for 15min at 4℃, transfer 400μL / tube of aqueous phase to a new EP tube, add 500μL / tube of isopropanol, mix well, and let stand at 4℃ for 10min. Centrifuge at 12000rpm for 10min at 4℃, observe with the naked eye the white precipitate at the bottom of the EP tube, discard the supernatant, and wash the RNA with 1mL / well 75% ethanol. Centrifuge at 7500rpm for 5min at 4℃, discard the supernatant, aspirate the excess residual liquid with a pipette, add 40μL / tube of enzyme-free water to dissolve the RNA, and then heat in a metal bath at 55℃ for 10min. The viral RNA expression level was detected by qRT-PCR, and the viral RNA level was detected by One Step RT-PCR kit for absolute quantification. The primer and probe sequences are as follows:
[0084] Forward primer, 5′-GGGTCCCTGAAGGAGTTGTAAA-3′
[0085] Reverse primer, 5′-TGCCTTCACCAAGACTATCAATGT-3′
[0086] Probe, 5′-FAM-TTCTGTCTTGCTGGCTCCGCGC-TAMRA-3′
[0087] Huh7 cells were inoculated into 12-well plates at the above density, and placed in an incubator until the cells filled the 12-well plates. The supernatant samples collected above were taken out from the -80°C refrigerator, and the supernatant samples were diluted 3 times with DMEM medium containing 2% FBS, and a total of 5 different concentrations were diluted for standby use. The 12-well plate was taken out from the incubator, the liquid was discarded, and 500 μL / well of the dilution of the supernatant samples of different concentrations were added and incubated for 2 hours to allow the virus to adsorb on the cell surface. Subsequently, the supernatant was discarded, and the cells were rinsed twice with 1 mL / well PBS solution. 2% agarose medium was prepared in advance. 2% low-melting point agarose required high-temperature heating in a microwave oven for 5 minutes. It was prepared in a ratio of 1:1 between 2×DMEM medium and 2% low-melting point agarose, and placed in a constant temperature incubator for standby use. 1 mL of 2% agarose medium was added, and the 12-well plate was placed in a 4°C refrigerator to cool for 10 minutes, and the cells were transferred to the incubator for continued culture. After 3-4 days of cell culture, obvious cytopathic effects were observed. 1 mL of 4% formaldehyde solution was added to each well and fixed at room temperature for 4 hours. The 2% agarose medium was washed off with running water, and an appropriate amount of 1% crystal violet staining solution was added to each well and stained at room temperature for 10 minutes. The crystal violet staining solution was rinsed with running water, and the plaques were counted after drying to calculate the PFU of the sample.
[0088] (2) Data Analysis
[0089]
[0090] Statistical analysis was performed using one-way ANOVA using GraphPad Prism 8 software, and significant differences were considered when p < 0.05.
[0091] (3) Experimental results
[0092] The experimental results are shown in Tables 4 to 6 and Figure 3 As shown, doxorcalciferol, alphacalciferol, and alpha-hydroxyvitamin D4 inhibited the replication of SFTSV RNA in a dose-dependent manner ( Figure 3 AC), and also inhibited the production of infectious virus particles in the supernatant ( Figure 3 DF).
[0093] Table 4. In vitro antiviral experiments of doxorcalciferol
[0094]
[0095] Table 5. In vitro antiviral experiments of alphacalcidol
[0096]
[0097] Table 6. In vitro antiviral experiments of alpha hydroxyvitamin D4
[0098]
[0099]
[0100] Example 3 Experiment in which vitamin D analogs reduce viremia in vivo and protect mice from lethal infection with SFTSV
[0101] (1) Experimental animals
[0102] The SPF-grade one-day-old ICR female mice and 6-week-old BALB / c female mice used in this example were purchased from Beijing Weitonglihua Experimental Animal Co., Ltd. All animal experiments were approved by the Animal Care and Use Committee of Beijing Institute of Materia Medica (approval number: IACUC-DWZX-2022-622).
[0103] (3) Experimental methods
[0104] Six-week-old BALB / c female mice were randomly divided into a drug-treated group and a virus-controlled group. The candidate compound or PBS solution was then administered by gavage, and the administration time was set before, during, and after the challenge every 12 hours, for a total of 3 times. The dosage of doxorcalciferol was set at 30 μg / kg and 15 μg / kg, respectively, and the dosage of alphacalciferol was set at 30 μg / kg and 15 μg / kg, respectively. The mice were challenged by intraperitoneal injection, and the infection dose was about 1×10 5 PFU / mouse, virus dilution volume 100μL / mouse. Prepare 1mL / tube of TRIzol in advance TM Reagents, 24 hours after infection, remove the eyeballs and collect blood, detect the viral RNA expression level by qRT-PCR, and use the One Step RT-PCR kit to detect the viral RNA level for absolute quantification. The primer and probe sequences are as follows:
[0105] Forward primer, 5′-GGGTCCCTGAAGGAGTTGTAAA-3′
[0106] Reverse primer, 5′-TGCCTTCACCAAGACTATCAATGT-3′
[0107] Probe, 5′-FAM-TTCTGTCTTGCTGGCTCCGCGC-TAMRA-3′
[0108] One-day-old ICR suckling mice were randomly divided into a compound-treated group and a virus-controlled group. The virus was challenged by intraperitoneal injection with an infection dose of approximately 5×10 5PFU / mouse, virus dilution volume 25μL / mouse. According to the set compound concentration, the dosage of doxorcalciferol was set to 0.3μg / kg, and the dosage of alphacalciferol was set to 0.6μg / kg and 0.3μg / kg, respectively. 4h after virus inoculation, the mice were given drugs by intraperitoneal injection or PBS solution treatment, and then every 24h for 8 consecutive days, for a total of 9 times. The survival and weight changes of one-day-old ICR suckling mice were recorded every day and observed for 21 consecutive days.
[0109] (3) Data analysis
[0110] Statistical analysis was performed using one-way ANOVA and nonparametric t-test using GraphPad Prism 8 software. Survival curves were analyzed using the Log-rank test. When p < 0.05, a significant difference was considered.
[0111] (4) Experimental results
[0112] The experimental results are shown in Tables 7 to 8 and Figure 4 As shown in Figure 2, viremia in BALB / c female mice was significantly reduced by treatment with doxorcalciferol and alphacalciferol ( Figure 4 A and D). Doxorubicin and alphacalciferol can prolong the survival time and improve the survival rate of ICR suckling mice infected with lethal doses of SFTSV ( Figure 4 The results showed that the cytokines could inhibit the growth of ICR mice (B, C), and had no significant effect on the body weight gain of ICR mice (E, F).
[0113] Table 7. Experiment on inhibition of viremia caused by SFTSV infection in BALB / c mice by doxorubicin and alphacalciferol
[0114]
[0115] Table 8. Experimental study on the protection of doxorubicin and alphacalcidol against lethal infection of SFTSV in 1-day-old ICR suckling mice - body weight records
[0116]
[0117] Example 4 Study on the mechanism of action of vitamin D analogs in inhibiting viral infection
[0118] (1) Experimental plan
[0119] Huh7 cells were cultured at a rate of approximately 2 × 10 5Cells / well density were inoculated in 12-well plates. The test compound and positive control compound T-705 were diluted in advance, and the infection dose MOI was set to 0.01. Four experimental groups with different time periods were set up, namely, stage I (-2 to 0 h), stage II (0 to 2 h), stage III (0 to 24 h), and stage IV (2 to 24 h). The drug addition sequence diagram ( Figure 5 A) Compounds were added at different time points. At the -2h time point, the experimental group cells of stage I were pre-treated with the test compound before virus infection, and 500μL / well compound diluent was added after discarding the liquid, and 500μL DMEM medium containing 2% FBS was supplemented. The remaining experimental groups and the virus control group were supplemented with 1mL DMEM medium containing 2% FBS. At the 0 time point, the experimental group of stage I (-2~0h) was rinsed 3 times with 1mL PBS solution to remove the compound residue, and 500μL DMEM medium containing 2% FBS was added; 500μL / well compound diluent was added to the experimental groups of stage II (0~2h) and stage III (0~24h); 500μL / well DMEM medium containing 2% FBS was supplemented to the experimental group of stage IV (2~24h) and the virus control group, and then 500μL / well virus diluent was added to each group and incubated for 2h. At the 2h time point, each group was rinsed 3 times with 1mL PBS solution to remove compound residues and virus residues. 500μL / well compound diluent and 500μL DMEM medium containing 2% FBS were added to the experimental groups of stage III (0-24h) and stage IV (2-24h), respectively, and 1mL DMEM medium containing 2% FBS was added to the other wells. After 24h of cell culture, 1mL / well TRIzol lysis solution was added, and the samples were allowed to stand at room temperature for 1min, and then transferred to 1.5mL EP tubes. Total RNA in the cells was extracted, and the viral RNA level was detected by One Step RT-PCR kit for absolute quantification. The primer and probe sequences are as follows:
[0120] Forward primer, 5′-GGGTCCCTGAAGGAGTTGTAAA-3′
[0121] Reverse primer, 5′-TGCCTTCACCAAGACTATCAATGT-3′
[0122] Probe, 5′-FAM-TTCTGTCTTGCTGGCTCCGCGC-TAMRA-3′
[0123] (2) Data Analysis
[0124] Statistical analysis was performed using one-way ANOVA with GraphPad Prism 8 software, and significant differences were considered when p < 0.05.
[0125] (3) Experimental results
[0126] The experimental results are shown in Tables 9 to 11 and Figure 5 As shown in the figure, the viral RNA level has not decreased after pretreatment with doxorcalciferol, alphacalciferol and alpha hydroxyvitamin D4 and co-incubation of drugs and viruses for 2 hours, indicating that doxorcalciferol, alphacalciferol and alpha hydroxyvitamin D4 have not yet affected the virus adsorption and entry stages. When vitamin D analogs are added after the virus infects the cells or during the entire process of virus infection, SFTSV RNA replication is significantly impeded, and the inhibition rate can reach about 50%. The trend is consistent with the positive drug T705 known to act on the virus replication stage, indicating that doxorcalciferol, alphacalciferol and alpha hydroxyvitamin D4 may act on the post-entry stage of virus infection.
[0127] Table 9. Experimental verification of the mechanism of action of doxorubicin against SFTSV
[0128] SFTSV infection stages Ⅰ Ⅱ Ⅲ Ⅳ Virus control group Doxorubicin(%) 110.52±10.52 104.25±1.75 66.79±1.215 65.69±10.69 100.00±0.00 T-705(%) 99.06±4.95 93.77±14.23 63.69±4.32 75.20±1.80 100.00±0.00
[0129] Table 10. Experimental verification of the mechanism of action of alphacalcidol against SFTSV
[0130] SFTSV infection stages Ⅰ Ⅱ Ⅲ Ⅳ Virus control group Alphacalcidol (%) 137.12±10.50 154.23±19.78 64.79±8.24 67.42±15.71 100.00±0.00 T-705(%) 125.36±29.30 119.57±19.84 43.37±13.77 45.93±8.67 100.00±0.00
[0131] Table 11. Experimental verification of the mechanism of action of alpha hydroxyvitamin D4 against SFTSV
[0132] SFTSV infection stages Ⅰ Ⅱ Ⅲ Ⅳ Virus control group Alpha hydroxyvitamin D4 (%) 137.17±16.25 118.36±27.47 53.83±9.39 56.03±14.32 100.00±0.00 T-705(%) 125.36±29.30 119.57±19.84 43.37±13.77 45.93±8.67 100.00±0.00
[0133] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and substitutions may be made to those details based on all the teachings disclosed, and these changes are within the scope of protection of the present invention. The full scope of the present invention is given by the attached claims and any equivalents thereof.
Claims
1. Use of a compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates in the preparation of a medicament, wherein the medicament is used to treat a fever with thrombocytopenia syndrome virus infection or a disease caused by a fever with thrombocytopenia syndrome virus infection in a subject, in: represents a single bond or a double bond, R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-6 Alkyl or C 1-6 Alkyl-C(O)-O-.
2. Use of a pharmaceutical composition in the preparation of a drug, wherein the pharmaceutical composition contains a compound represented by formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof, and a pharmaceutically acceptable carrier, and the drug is used to treat fever with thrombocytopenia syndrome virus infection or a disease caused by fever with thrombocytopenia syndrome virus infection in a subject, in: represents a single bond or a double bond, R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Alkyl-C(O)-O-.
3. The use according to claim 1 or 2, wherein the disease caused by FET virus infection is FET.
4. The use of claim 1 or 2, wherein the disease caused by fever with thrombocytopenia syndrome virus infection is selected from acute fever, cough, fatigue, gastrointestinal symptoms, leukopenia and / or thrombocytopenia, multi-organ hemorrhage, disseminated intravascular coagulation and viral encephalitis.
5. Use of the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates in the preparation of a medicament, wherein the medicament is used to inhibit the replication or reproduction of fever with thrombocytopenia syndrome virus in a subject, in: represents a single bond or a double bond, R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-6 Alkyl or C 1-6 Alkyl-C(O)-O-.
6. Use of a pharmaceutical composition in the preparation of a drug, wherein the pharmaceutical composition contains a compound represented by formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof, and a pharmaceutically acceptable carrier, and the drug is used to inhibit the replication or reproduction of fever with thrombocytopenia syndrome virus in a subject, in: represents a single bond or a double bond, R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-6 Alkyl or C 1-6 Alkyl-C(O)-O-.
7. Use of the compound represented by formula I, its geometric isomers, its pharmaceutically acceptable salts, its solvates or its hydrates in the preparation of a drug, wherein the drug is a fever with thrombocytopenia syndrome virus inhibitor, in: represents a single bond or a double bond, R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-6 Alkyl or C 1-6 Alkyl-C(O)-O-.
8. Use of a pharmaceutical composition in the preparation of a drug, wherein the pharmaceutical composition comprises a compound represented by formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof, and a pharmaceutically acceptable carrier, and the drug is a fever with thrombocytopenia syndrome virus inhibitor, in: represents a single bond or a double bond, R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-6 Alkyl or C 1-6 Alkyl-C(O)-O-.
9. The method of claim 1, wherein R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-4 Alkyl or C 1-4 Alkyl-C(O)-O-; Preferably, R1, R2 and R3 are each independently hydrogen, hydroxyl, C 1-3 Alkyl or C 1-3 Alkyl-C(O)-O-; Preferably, R1, R2 and R3 are each independently hydrogen, hydroxyl, methyl, ethyl, CH3-C(O)-O- or CH3-CH2-C(O)-O-; Preferably, R1 is hydroxy, R2 is hydrogen, hydroxy or methyl, and R3 is hydrogen, hydroxy or methyl; Preferably, R1 is hydroxy, R2 is hydrogen, hydroxy or methyl, and R3 is hydrogen or hydroxy; Preferably, R1 is hydroxy, R2 is hydrogen or methyl, and R3 is hydrogen; Preferably, the compound is doxorcalciferol, alphacalciferol or alpha hydroxyvitamin.
10. The use according to any one of claims 1, 2, 5-8, wherein the subject is a mammal, such as bovine, equine, caprine, porcine, canine, feline, rodent, primate, preferably human, cat, dog or pig.
Citation Information
Patent Citations
Application of composition in preparing drug for preventing and / or treating virus of severe fever with thrombocytopenia syndrome
CN110279693A
